4.6 Article

Mechanical-Stretch of C2C12 Myoblasts Inhibits Expression of Toll-Like Receptor 3 (TLR3) and of Autoantigens Associated with Inflammatory Myopathies

Journal

PLOS ONE
Volume 8, Issue 11, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0079930

Keywords

-

Funding

  1. National Natural Science Foundation of China [81171724, 81371924]
  2. National Basic Research Program of China [2012CB619104]
  3. Guang Dong Provincial Science and Technology Program [2012B031800146]

Ask authors/readers for more resources

Recent studies in patients suffering from inflammatory autoimmune myopathies suggested that moderate exercise training improves or at least stabilizes muscle strength and function without inducing disease flares. However, the precise mechanisms involved in this beneficial effect have not been extensively studied. Here we used a model of in vitro stretched C2C12 myoblasts to investigate whether mechanical stretch could influence myoblast proliferation or the expression of proinflammatory genes. Our results demonstrated that cyclic mechanical stretch stimulated C2C12 cell cycling and early up-regulation of the molecules related to mechanical-stretch pathway in muscle (calmodulin, nNOS, MMP-2, HGF and c-Met). Unexpectedly, mechanical stretch also reduced the expression of TLR3 and of proteins known to represent autoantigens in inflammatory autoimmune myopathies (Mi-2, HRS, DNA-PKcs, U1-70). Interestingly, stimulation or inhibition of calmodulin, NOS, HGF or c-Met molecules in vitro affected the expression of autoantigens and TLR3 proteins confirming their role in the inhibition of autoantigens and TLR3 during mechanical stretch. Overall, this study demonstrates for the first time that mechanical stretch could be beneficial by reducing expression of muscle autoantigens and of pro-inflammatory TLR3 and may provide new insight to understand how resistance training can reduce the symptoms associated with myositis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemical Research Methods

Flow cytometry: An accurate tool for screening P2RX7 modulators

Amelie Barczyk, Helene Bauderlique-Le Roy, Nathalie Jouy, Nicolas Renault, Audrey Hottin, Regis Millet, Valerie Vouret-Craviari, Sahil Adriouch, Thierry Idziorek, Xavier Dezitter

Summary: P2RX7 is a poorly selective ATP-gated ion channel with important physiological and pathological implications, making it a potential therapeutic target in several diseases. Novel screening methods based on flow cytometry and spectral flow cytometry have been developed to efficiently measure P2RX7 activity and assess the efficacy of modulators. Spectral cytometry appears to be a useful tool for drug candidate screening by simultaneously evaluating multiple biological activities and correcting for the autofluorescence of compounds screened.

CYTOMETRY PART A (2021)

Article Multidisciplinary Sciences

A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy

Laetitia Douguet, Serena Janho Dit Hreich, Jonathan Benzaquen, Laetitia Seguin, Thierry Juhel, Xavier Dezitter, Christophe Duranton, Bernhard Ryffel, Jean Kanellopoulos, Cecile Delarasse, Nicolas Renault, Christophe Furman, Germain Homerin, Chloe Feral, Julien Cherfils-Vicini, Regis Millet, Sahil Adriouch, Alina Ghinet, Paul Hofman, Valerie Vouret-Craviari

Summary: A small subpopulation of non-small cell lung cancer patients respond to immunotherapies, and the development of HEI3090 as a chemical modulator of the purinergic P2RX7 receptor may enhance anti-tumor immune responses and sensitize lung cancer to PD-1 therapy in preclinical models.

NATURE COMMUNICATIONS (2021)

Editorial Material Medicine, Research & Experimental

ASC nanobodies to counteract the consequences of inflammasome activation

Sahil Adriouch, Pablo Pelegrin

Summary: The study developed specific anti-ASC nanobodies that effectively disaggregate formed ASC oligomers and treat inflammatory diseases in animal models. This approach represents a novel biologic-based treatment for inflammasomes-initiated inflammatory diseases.

EMBO MOLECULAR MEDICINE (2022)

Review Biochemistry & Molecular Biology

Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network

Gabriel Ichim, Benjamin Gibert, Sahil Adriouch, Catherine Brenner, Nathalie Davoust, Solange Desagher, David Devos, Svetlana Dokudovskaya, Laurence Dubrez, Jerome Estaquier, Germain Gillet, Isabelle Guenal, Philippe P. Juin, Guido Kroemer, Patrick Legembre, Romain Levayer, Stephen Manon, Patrick Mehlen, Olivier Meurette, Olivier Micheau, Bernar Mignotte, Florence Nguyen-Khac, Nikolay Popgeorgiev, Jean-Lu Poyet, Muriel Priault, Jean-Ehrlan Ricci, Franck B. Riquet, Santos A. Susin, Magal Suzanne, Pierre Vacher, Ludivine Walter, Bertran Mollereau

Summary: Since the Nobel Prize was awarded more than twenty years ago for discovering the core apoptotic pathway in C. elegans, researchers around the world have conducted extensive research on apoptosis and various other forms of regulated cell death. Although there are still many aspects of regulated cell death that need to be clarified in specific cell subtypes and disease conditions, the last decade has seen the description of multiple cell death modalities, some of which have been successfully used in clinical therapy. To keep research into cell death alive, francophone researchers from several institutions in France and Belgium established the French Cell Death Research Network (FCDRN), which is at the forefront of emerging topics in cell death research. These research efforts will enhance our mechanistic knowledge of regulated cell death and its therapeutic applications in the coming years.

BIOMOLECULES (2022)

Article Pharmacology & Pharmacy

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs

Carolina Pinto-Espinoza, Charlotte Guillou, Bjoern Rissiek, Maximilian Wilmes, Ehsan Javidi, Nicole Schwarz, Marten Junge, Friedrich Haag, Nastassia Liaukouskaya, Nicola Wanner, Annette Nicke, Catelijne Stortelers, Yossan-Var Tan, Sahil Adriouch, Tim Magnus, Friedrich Koch-Nolte

Summary: This study evaluated the ability of P2X7-specific nanobodies to reach and block P2X7 on microglia. The results showed that intracerebral injection of nanobodies achieved faster and more effective blockade of microglial P2X7 compared to intravenous injection. Additionally, the endogenous production of nanobody-encoding AAVs resulted in long-term occupancy and blockade of P2X7 on microglia.

FRONTIERS IN PHARMACOLOGY (2022)

Article Immunology

Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo

Melanie Demeules, Allan Scarpitta, Romain Hardet, Henri Gonde, Catalina Abad, Marine Blandin, Stephan Menzel, Yinghui Duan, Bjoern Rissiek, Tim Magnus, Anna Marei Mann, Friedrich Koch-Nolte, Sahil Adriouch

Summary: Adenosine triphosphate (ATP) is a danger signal that accumulates in injured tissues, inflammatory sites, and the tumor microenvironment. It promotes tumor growth and anti-tumor immune responses via the P2X7 receptor. P2X7, CD39, and CD73 are novel purinergic checkpoints that can be targeted for cancer treatment. Blocking P2X7 inhibits tumor growth, while a nanobody-based biologic targeting P2X7 enhances tumor control and immune responses when used in combination with chemotherapy. A bi-specific nanobody-based biologic targeting PD-L1 and CD73 has a potent anti-tumor effect.

FRONTIERS IN IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

The Angiogenesis Inhibitor Isthmin-1 (ISM1) Is Overexpressed in Experimental Models of Glomerulopathy and Impairs the Viability of Podocytes

Virgilia Sahiri, Jonathan Caron, Elena Roger, Christophe Desterke, Khalil Ghachem, Inna Mohamadou, Justine Serre, Niki Prakoura, Soraya Fellahi, Sandrine Placier, Sahil Adriouch, Lu Zhang, Christos E. Chadjichristos, Christos Chatziantoniou, Hans Kristian Lorenzo, Jean-Jacques Boffa

Summary: A study found that the progression of FSGS is correlated with podocyte apoptosis, in which ISM1 plays an important role. Overexpression of ISM1 was observed during FSGS progression and localized in glomeruli, while it partially restored when the disease improved. Further in vitro experiments demonstrated that ISM1 interacts with its receptors GRP78 and integrin alpha v beta 5 on podocytes, inducing apoptosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Animal Models for the Investigation of P2X7 Receptors

Ronald Sluyter, Sahil Adriouch, Stephen J. Fuller, Annette Nicke, Reece A. Sophocleous, Debbie Watson

Summary: The P2X7 receptor is a ligand-gated cation channel that is activated by extracellular adenosine 5'-triphosphate. Animal models have played a crucial role in understanding the physiological and pathophysiological functions of P2X7 in human health and disease. This article highlights the contributions of animal models in generating tools for studying P2X7, such as specific antibodies, recombinant receptors, and pharmacokinetic testing of P2X7 antagonists. It also discusses the use of mouse, rat, and other animal models in studying P2X7, including disease models, knockout mice, reporter mice, and humanized mice.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Medicine, Research & Experimental

Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy

Ann-Christin Franke, Romain Hardet, Lisa Prager, Martin Bentler, Melanie Demeules, Philipp John-Neek, Nico Martin Jaeschke, Teng Cheong Ha, Ulrich Thorsten Hacker, Sahil Adriouch, Hildegard Buening

Summary: Immunotherapy combined with anti-tumor vaccines has shown promising results in improving treatment outcomes for various cancer types. In this study, adeno-associated virus (AAV) vectors were used as a potent cancer vaccine platform that induces strong and long-lasting antigen-specific immune responses. The AAV vector-based vaccine effectively protected mice against tumor growth in different tumor models, even when challenged with tumors at a late stage. This approach of decorating AAV vector particles with antigens by capsid engineering represents a versatile and efficient vaccine strategy for cancer immunotherapy.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Review Biotechnology & Applied Microbiology

Understanding and Tackling Immune Responses to Adeno-Associated Viral Vectors

Helena Costa-Verdera, Carmen Unzu, Erika Valeri, Sahil Adriouch, Gloria Gonzalez Aseguinolaza, Federico Mingozzi, Anna Kajaste-Rudnitski

Summary: As the clinical experience in AAV vector-based gene therapies grows, there is a need to better understand and control the host immune responses. Our current understanding of the immune responses to AAV gene therapies is limited, which is further hindered by the lack of replication of clinical findings in preclinical animal models.

HUMAN GENE THERAPY (2023)

Article Medicine, Research & Experimental

Modifying immune responses to adeno-associated virus vectors by capsid engineering

Martin Bentler, Romain Hardet, Moritz Ertelt, Daniela Rudolf, Dorota Kaniowska, Andreas Schneider, Florian W. R. Vondran, Clara T. Schoeder, Marion Delphin, Julie Lucifora, Michael Ott, Ulrich T. Hacker, Sahil Adriouch, Hildegard Buening

Summary: In this study, the researchers successfully reduced immune responses in gene therapy by inserting a peptide into the AAV2 capsid. The novel capsid variant, AAV2.MB453, showed improved transduction efficiency and reduced innate and adaptive immune responses in human cells.

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT (2023)

Meeting Abstract Biotechnology & Applied Microbiology

AAV-mediated induction of immunogenic cell death to promote anti-tumor immune responses

A. Scarpitta, R. Hardet, M. Bentler, M. Demeules, M. Blandin, U. Hacker, H. Buening, O. Boyer, S. Adriouch

HUMAN GENE THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Nanobodies as versatile ligands to retarget AAV

W. Schaefer, N. Richter, S. Jargalsaikhan, F. Haag, I. Braren, C. Thirion, S. Adriouch, F. Koch-Nolte, A. M. Mann

HUMAN GENE THERAPY (2022)

Meeting Abstract Clinical Neurology

Modulation of P2X7 receptor activity in experimental autoimmune encephalomyelitis models

C. Guillou, M. Fourny, C. Abad, S. Adriouch, Y. -V. Tan

MULTIPLE SCLEROSIS JOURNAL (2022)

Meeting Abstract Immunology

A methodological approach using rAAV vectors encoding nanobody-based biologics to evaluate ARTC2.2 and P2X7 in vivo

Henri Gonde, Melanie Demeules, Romain Hardet, Allan Scarpitta, Marten Junge, Carolina Pinto Espinoza, Remi Varin, Friedrich Koch Nolte, Olivier Boyer, Sahil Adriouch

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

No Data Available